AI Article Synopsis
- This study examined the expression levels of 9 miRNAs in CD8+ T cells from asthmatic patients and compared them to healthy controls.
- The researchers found no significant differences in miRNA expression between the two groups, but noted that fluticasone furoate and vilanterol had the most notable impact on these miRNAs.
- Correlations between miRNAs, particularly between miR-106a and miR-126 in asthmatic patients, were statistically significant, suggesting that these correlations might be more important than changes in miRNA expression levels themselves.
Article Abstract
In this study, we first tried to determine whether the expression level of 9 miRNAs in the peripheral blood CD8+ T cells of asthmatic patients varies from that of controls, and secondly, we investigated the effects of fluticasone furoate and vilanterol on the expression level of these miRNAs. Fifteen subjects including 8 healthy individuals and 7 asthmatic patients were included in this study. CD8+T cells were isolated from participants' peripheral blood by a negative selection method using magnetic-activated cell sorting (MACS). The expression of 9 miRNAs was examined between the healthy individuals and asthmatic patients. Then the expression level of 9 miRNAs before and after treatment with the drugs was examined by quantitative real-time PCR. No significant changes in the expression level of 9 miRNAs were observed in asthmatic patients compared to the healthy controls. Fluticasone and vilanterol, in combination, had the greatest effect on miRNA expression. MiR-150 and miR-106a were the most and the least miRNAs, respectively, present in CD8+ T cells of patients and controls. MiR-106a and miR-126 had a positive correlation in CD8+ cells of asthmatic patients. Although no significant difference in the expression level of studies miRNAs was observed, the correlations among miRNAs were significant. Therefore, we suggest that the correlation between miRNAs would be a very important factor in physiological and pathological conditions in healthy individuals and asthmatic patients. Such a miRNA-miRNA correlation network can be even more critical than any changes in the variation of their expression in the CD8+ T cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18502/ijaai.v18i4.1414 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of self-reported asthma in type 1 diabetes children and its associated predictors.
Allergol Immunopathol (Madr)
January 2025
Prince Sattam bin Abdulaziz Research Chair for Epidemiology and Public Health, Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Asthma is considered one of the most common and serious noncommunicable diseases, with high morbidity and mortality rates in both children and adults.
Objectives: To estimate the frequency and to determine the associated factors of self-reported asthma among children diagnosed with type 1 diabetes.
Methods: A cross-sectional study design was employed, and 175 subjects having type 1 diabetes for more than 1 year were included from the pediatrics endocrine clinic.
Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry.
Allergol Immunopathol (Madr)
January 2025
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.
View Article and Find Full Text PDFChanges in serum periostin levels in uncontrolled asthma in children (DADO phase 2 study).
Allergol Immunopathol (Madr)
January 2025
Department of Biological Sciences, University of Extremadura, Spain.
Objective: Asthma is an inflammatory airway condition and the most common chronic disease in children. However, there is a lack of biological markers for asthma, especially in children. This study aimed to analyze the changes in periostin levels in children with uncontrolled asthma after 12 months of optimized management.
View Article and Find Full Text PDFReal-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis.
J Asthma
January 2025
GSK, Upper Providence, PA, USA.
Objective: Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period.
Methods: This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015-September 2019) using the Merative MarketScan Commercial and Medicare Databases.
Use and limitations of clinical data in the identification and classification of low molecular weight chemicals (LMWCs) as respiratory sensitizers: recommendations for improvement.
Crit Rev Toxicol
January 2025
Syngenta, Bracknell, United Kingdom.
While progress has been made in recent years, there are still no suitable and accepted , or models that can be used to accurately predict whether a chemical substance has the intrinsic property to cause immune-mediated chemical respiratory allergy, typically manifested as allergic asthma or allergic rhinitis which represents a severe health hazard. Regulatory authorities have relied primarily on clinical evidence (case reports, clinical databases, worker exposure studies) to classify substances as respiratory sensitizers, but this evidence can lack a proven immunological mechanism which is necessary to identify substances which can cause life-long sensitization and clinically relevant allergic symptoms in the respiratory tract in an exposed population (such respiratory allergens may be considered as "true" sensitizers, in analogy to the definition of skin sensitization, and in contrast to respiratory irritants). In light of this, the European Center for Ecotoxicology and Toxicology of Chemicals convened a Task Force to evaluate the types of clinical methods and data sources and the implications of relying on such data for regulatory decision making from a scientific perspective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!